Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels

Journal of Hypertension

Volumn 29, Issue 9, 2011, Pages 1757-1764

  Schneider, Markus P ^a,b   Schmidt, Bernhard M ^c   John, Stefan ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

cholesterol; endothelium; hydroxymethylglutaryl CoA reductase inhibitors; hypertension; impedance plethysmography; inflammation; nitric oxide; oxidative stress

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; ASCORBIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; FLUINDOSTATIN; GLUTATHIONE; GLUTATHIONE DISULFIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROPRUSSIDE SODIUM; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE; FOREARM BLOOD FLOW; HUMAN; HYPERTENSION; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

EID: 80051924459     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834a509a     Document Type: Article

References (50)

1. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81:1762-1767. (Pubitemid 20183824)
2. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27. (Pubitemid 20209468)
3. Yoshida M, Imaizumi T, Ando S, Hirooka Y, Harada S, Takeshita A. Impaired forearm vasodilatation by acetylcholine in patients with hypertension. Heart Vessels 1991; 6:218-223.
4. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endotheliumderived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474. (Pubitemid 23133089)
5. Taddei S, Ghiadoni L, Virdis A, Buralli S, Salvetti A. Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999; 100:1400-1405. (Pubitemid 29451699)
6. Schneider MP, Delles C, Schmidt BM, Oehmer S, Schwarz TK, Schmieder RE, et al. Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am J Hypertens 2005; 18:1111-1117. (Pubitemid 41139911)
7. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229. (Pubitemid 28265383)
8. On YK, Kim CH, Sohn DW,Oh BH, Lee MM, Park YB, et al. Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. Korean J Intern Med 2002; 17:131-137.
9. Ghiadoni L, Taddei S, Virdis A, Sudano I, Di Legge V, Meola M, et al. Endothelial function and common carotid artery wall thickening in patients with essential hypertension. Hypertension 1998; 32:25-32. (Pubitemid 28324120)
10. Millgard J, Hagg A, Kahan T, Landelius J, Malmqvist K, Sarabi M, et al. Left ventricular hypertrophy is associated with an attenuated endotheliumdependent vasodilation in hypertensive men. Blood Press 2000; 9:309-314. (Pubitemid 32099088)
11. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 1999; 99:1991-1996. (Pubitemid 29183896)
12. Ceravolo R, Maio R, Pujia A, Sciacqua A, Ventura G, Costa MC, et al. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients. J Am Coll Cardiol 2003; 41:1753-1758. (Pubitemid 36584248)
13. Perticone F, Maio R, Perticone M, Sciacqua A, Shehaj E, Naccarato P, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients. Circulation 2010; 122:379-384.
14. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-196. (Pubitemid 32655837)
15. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104:2673-2678. (Pubitemid 33108132)
16. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 (Suppl 2):S314-S321.
17. On YK, Kim CH, Oh BH, Lee MM, Park YB. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res 2002; 25:365-371.
18. Perticone F, Ceravolo R, Maio R, Ventura G, Iacopino S, Cuda G, et al. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. Cardiovasc Res 1999; 41:299-306. (Pubitemid 29016070)
19. Taddei S, Virdis A, Ghiadoni L, Magagna A, Favilla S, Pompella A, et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001; 37:943-948. (Pubitemid 32221618)
20. Taddei S, Virdis A, Ghiadoni L, Magagna A, Pasini AF, Garbin U, et al. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19:1379-1386. (Pubitemid 32730454)
21. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16:447-456. (Pubitemid 28195854)
22. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104:511-514. (Pubitemid 32738117)
23. Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther 2009; 27:151-158.
24. von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001; 19:1813-1818. (Pubitemid 32924947)
25. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24: 499-505. (Pubitemid 24296474)
26. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996; 27:371-376. (Pubitemid 26083054)
27. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21:1145-1151. (Pubitemid 23106189)
28. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-128. (Pubitemid 36143430)
29. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35:501-506. (Pubitemid 30054224)
30. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, doubleblind study. Circulation 1998; 98:211-216. (Pubitemid 28337611)
31. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95:1126-1131. (Pubitemid 27097821)
32. John S, Delles C, Jacobi J, Schlaich MP, Schneider M, Schmitz G, et al. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37:1351-1358.
33. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipidindependent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149: 473.
34. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021. (Pubitemid 38781100)
35. Tousoulis D, Papageorgiou N, Androulakis E, Paroutoglou K, Stefanadis C. Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Expert Opin Investig Drugs 2010; 19:1395-1412.
36. Lenders J, Janssen GJ, Smits P, Thien T. Role of the wrist cuff in forearm plethysmography. Clin Sci (Lond) 1991; 80:413-417.
37. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762. (Pubitemid 47356612)
38. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
39. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 2003; 93:e98-e103.
40. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104:376-379. (Pubitemid 32678263)
41. Mancia G, Parati G, Revera M, Bilo G, Giuliano A, Veglia F, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over h: evidence from PHYLLIS randomised double blind trial. BMJ 2010; 340:c1197.
42. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30:57-63. (Pubitemid 27306347)
43. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens 2000; 18:363-374. (Pubitemid 30209715)
44. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
45. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
46. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
47. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-1965. (Pubitemid 32568149)
48. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003; 34:551-557. (Pubitemid 36206363)
49. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452. (Pubitemid 34263276)
50. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102:3104-3110.